E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 10/20/2006 in the Prospect News Biotech Daily and Prospect News Convertibles Daily.

OSI Pharmaceuticals says holders may convert 2% convertibles through Dec. 29

By Laura Lutz

Chicago, Oct. 20 - OSI Pharmaceuticals, Inc. announced that its 2% convertible senior notes due 2025 are convertible through Dec. 29.

The notes became convertible because the company's stock closed at or above $35.32 for the 20 trading days within the 30 trading days ended on Sept. 29.

The conversion rate of the notes is 33.9847 shares per $1,000 principal amount, or $29.43 per share.

There is $115 million principal amount of the notes outstanding.

OSI Pharmaceuticals is a pharmaceutical company based in Melville, N.Y.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.